Celularity Inc
For the period ended Sep 30, 2024. Filed Dec 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Dec 6, 2024
CELU$0.71-6.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(In thousands, except share and per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Revenues | ||||
| Product sales, net | $3,393 | $1,684 | $26,199 | $3,633 |
| Services | 1,292 | 1,427 | 3,857 | 4,062 |
| License, royalty and other | 4,611 | 675 | 6,032 | 2,964 |
| Total net revenues | 9,296 | 3,786 | 36,088 | 10,659 |
| Operating expenses | ||||
| Cost of revenues (excluding amortization of acquired intangible assets) | ||||
| Product sales | 547 | 557 | 2,888 | 1,486 |
| Services | 238 | 398 | 952 | 1,355 |
| License, royalty and other | 3,098 | 2,647 | 3,806 | 3,566 |
| Research and development | 3,915 | 5,182 | 13,558 | 30,737 |
| Software cease-use costs | - | 243 | - | 24,161 |
| Selling, general and administrative | 12,650 | 10,748 | 42,585 | 37,508 |
| Change in fair value of contingent consideration liability | - | - | - | (104,339) |
| Goodwill impairment | - | 82,714 | - | 112,347 |
| IPR&D impairment | - | - | - | 107,800 |
| Amortization of acquired intangible assets | 375 | 553 | 1,377 | 1,640 |
| Total operating expenses | 20,823 | 103,042 | 65,166 | 216,261 |
| Loss from operations | (11,527) | (99,256) | (29,078) | (205,602) |
| Other income (expense): | ||||
| Interest income | 77 | 23 | 254 | 205 |
| Interest expense | (1,752) | (971) | (4,452) | (2,352) |
| Change in fair value of warrant liabilities | 714 | 5,187 | (1,156) | 6,788 |
| Change in fair value of debt | (708) | 2,003 | (694) | (354) |
| Loss on debt extinguishment | - | - | (3,908) | - |
| Other expense, net | (2,902) | (862) | (5,565) | (4,527) |
| Total other income (expense) | (4,571) | 5,380 | (15,521) | (240) |
| Loss before income taxes | (16,098) | (93,876) | (44,599) | (205,842) |
| Income tax expense (benefit) | - | - | - | - |
| Net loss | $(16,098) | $(93,876) | $(44,599) | $(205,842) |
| Change in fair value of debt due to change in credit risk, net of tax | (2) | - | (2) | 2,541 |
| Other comprehensive (loss) income | (2) | - | (2) | 2,541 |
| Comprehensive loss | $(16,100) | $(93,876) | $(44,601) | $(203,301) |
| Share information: | ||||
| Net loss per share - basic and diluted | $(0.73) | $(4.98) | $(2.05) | $(11.86) |
| Weighted average shares outstanding - basic and diluted | 21,976,339 | 18,831,713 | 21,756,498 | 17,353,605 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.